CRISPR Therapeutics AG
CRISPR Therapeutics AG（CRSP）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · CRSP · 截至 2025年9月30日
股东结构概览
488
机构持有人数
▲ 9 vs Q2
$4.68B
机构持仓总市值
▲ $1.16B vs Q2
96.45M
总流通股
freeFloat 99.56%
72.25M
13F 申报持股数
▼ 264,492 vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
CRSP 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
ARK INVESTMENT MANAGEMENT LLC biological products, (no diagnostic substances) | 9.79M | 11.24% | 11.24% | $634.29B | Nov 12, 2025 | ▼ 395.6K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 7.05M | 8.10% | 8.10% | $456.92B | Nov 12, 2025 | ▲ 983.8K |
CAPITAL INTERNATIONAL INVESTORS biological products, (no diagnostic substances) | 5.65M | 6.49% | 6.49% | $366.13B | Nov 13, 2025 | ▲ 55.5K |
ORBIS ALLAN GRAY LTD biological products, (no diagnostic substances) | 4.98M | 5.72% | 5.72% | $322.89B | Nov 14, 2025 | ▲ 2.22M |
STATE STREET CORP biological products, (no diagnostic substances) | 4.01M | 4.60% | 4.60% | $259.71B | Nov 14, 2025 | ▲ 736.6K |
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. biological products, (no diagnostic substances) | 3.28M | 3.77% | 3.77% | $212.75B | Nov 14, 2025 | ▼ 400.4K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.36M | 2.72% | 2.72% | $153.25B | Nov 7, 2025 | ▲ 66.6K |
UBS GROUP AG biological products, (no diagnostic substances) | 2.34M | 2.69% | 2.69% | $151.59B | Nov 13, 2025 | ▼ 504.5K |
SUMITOMO MITSUI TRUST HOLDINGS, INC. biological products, (no diagnostic substances) | 2.16M | 2.48% | 2.48% | $140.23B | Oct 27, 2025 | ▼ 251.2K |
NIKKO ASSET MANAGEMENT AMERICAS, INC. biological products, (no diagnostic substances) | 2.16M | 2.48% | 2.48% | $140.18B | Nov 12, 2025 | ▼ 250.6K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
25
增持
+8.21M 股1
新建仓
首次建仓22
减持
−5.24M 股0
清仓
完全退出净股数变化（前50家）
+2.97M
+8.21M / −5.24M
净新增持仓人
+4
新建 1 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
CRSP 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
23
买入笔数
35
卖出笔数
0.66
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
KASINGER JAMES R. General Counsel and Secretary | May 29, 2026 | Award | 17,000 | — | — | 17.0K | Form 4 ↗ |
Patel Naimish Chief Medical Officer | May 29, 2026 | Award | 22,000 | — | — | 22.0K | Form 4 ↗ |
Prasad Raju Chief Financial Officer | May 29, 2026 | Award | 19,500 | — | — | 19.5K | Form 4 ↗ |
Patel Naimish Chief Medical Officer | May 29, 2026 | Sale | 3,786 | $55.62 | $210.6K | 19.4K | Form 4 ↗ |
KASINGER JAMES R. General Counsel and Secretary | Mar 23, 2026 | Sale | 3,182 | $46.78 | $148.9K | 94.3K | Form 4 ↗ |
KASINGER JAMES R. General Counsel and Secretary | Mar 20, 2026 | Award | 38,499 | $46.24 | $1.78M | 38.5K | Form 4 ↗ |
KASINGER JAMES R. General Counsel and Secretary | Mar 20, 2026 | Award | 25,000 | — | — | 25.0K | Form 4 ↗ |
Kulkarni Samarth Chief Executive Officer | Mar 23, 2026 | Sale | 10,020 | $46.78 | $468.7K | 255.5K | Form 4 ↗ |
Kulkarni Samarth Chief Executive Officer | Mar 20, 2026 | Award | 114,249 | $46.24 | $5.28M | 114.2K | Form 4 ↗ |
Kulkarni Samarth Chief Executive Officer | Mar 20, 2026 | Award | 81,875 | — | — | 81.9K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
CRISPR Therapeutics AG（CRSP）主要由机构投资者持有，机构持股比例约为 74.9%。公司内部人员持股约 0.44%，散户及公众持股约占剩余的 24.66%。
CRISPR Therapeutics AG 最大机构股东为 ARK INVESTMENT MANAGEMENT LLC，截至 September 30, 2025 持有约 9.79 million 股，占总流通股的 11.24%。
目前共有 488 家机构持有 CRSP 股票，合计持仓市值约 $4.68 billion，数据来源为最新 SEC 13F 申报。
常见问题
CRSP ownershipCRISPR Therapeutics AG（CRSP）主要由机构投资者持有，机构持股约 74.9%。最大股东为 ARK INVESTMENT MANAGEMENT LLC，持股比例 11.24%。内部人员持股约 0.44%。数据来源 SEC Form 13F，截至 September 30, 2025。